About Bruce Booth
Booth is an Atlas Venture partner focused on finding and developing new medicines and drug technology platforms. He also chairs Matchpoint Therapeutics. Matchpoint develops small-molecule medicines for immune diseases. He was the founding chief executive of Kymera Therapeutics and Nimbus Therapeutics. Before joining Atlas in 2005, he worked as a consultant at McKinsey & Company and an investor at Caxton Health Holdings. He has written about biotechnology and venture capital at LifeSciVC since 2011. During the winter, he volunteers as a coach with New England Disabled Sports. He holds a doctorate in molecular immunology from Oxford University and a B.S. in biochemistry, summa cum laude, from Penn State.
He chairs Kymera Therapeutics, Nimbus Therapeutics and HotSpot Therapeutics. He also chairs Matchpoint and Spolia Therapeutics. He serves on the Lifordi Immunotherapeutics and Sionna Therapeutics boards. He also serves on the Appalachian Mountain Club board. He previously served on boards of acquired Atlas companies. Celgene acquired Avila. Bial acquired Lysosomal Therapeutics. Takeda acquired Nimbus Lakshmi. BMS acquired Padlock Therapeutics. Alkermes acquired Rodin Therapeutics. Biogen acquired Stromedix. Sanofi acquired Vigil Neuroscience.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Bruce Booth in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Bruce Booth works with at each company, as listed on that company's latest Form D.


